An editorial reference, set with the care of an institutional document.

What Tirzepatide Legit is

Tirzepatide Legit is an independent editorial project that publishes summaries of the peer-reviewed research literature, FDA regulatory documents, and analytical-chemistry record relating to tirzepatide. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, repackage, distribute, broker, or arrange access to any product. We are not a verification service: we do not authenticate cartons, examine vials, or run lab tests on behalf of readers. Our work is editorial commentary on publicly available science and publicly available regulatory action.

What "legit" means in the domain name

The modifier "legit" in this site's name is editorial framing — a position the publisher occupies relative to the literature, not a claim about the site's services. The word "legit" is what readers type into search engines when they are trying to figure out whether the tirzepatide in front of them, or the source they are considering, is the FDA-approved product or something else. This site exists to help readers read the regulatory and analytical record themselves so they can answer that question with their own physician and pharmacist. It does not answer it for them, and it does not perform the verification on their behalf.

Editorial standards and sourcing

Every quantitative claim on this site is anchored to a peer-reviewed publication, an FDA-issued regulatory document, or a manufacturer-published technical reference. Clinical trial figures cite the New England Journal of Medicine, The Lancet, JAMA, or PNAS publications of the SURPASS, SURMOUNT, SUMMIT, SYNERGY-NASH, and SURPASS-CVOT programs. Mechanism and pharmacokinetic figures cite the original JCI Insight, PNAS, and Clinical Pharmacokinetics papers. Regulatory claims cite the FDA's published declaratory orders, drug safety communications, and the approved label.

We do not paraphrase claims from social media, telehealth-clinic marketing pages, or "research peptide" supplier sites. We do not republish anecdotes. We do not interview anonymous sources. The bibliography on /references is the complete sourcing list.

What we will not do

We will not name individual sellers as legitimate or illegitimate. The FDA, state boards of pharmacy, state medical boards, and the U.S. International Trade Commission name specific entities in their enforcement actions; those are the authoritative public records. We summarize the regulatory framework rather than maintain a parallel list.

We will not provide a verification service. The carton-scan check, the NDC lookup, the state-board lookups, and the physical inspection of a pen or vial are checks that readers should perform themselves, with their dispensing pharmacist and physician available to consult. We describe what those checks involve. We do not run them on anyone's behalf.

We will not recommend a dose, a titration schedule, an alternative source, or a treatment plan. The FDA-approved label, the trial protocols, and the reader's own licensed prescriber are the appropriate references for any prescribing decision.